Evidence map›Paper›PMID 36693865›Full record

ArticleScientific reports2023

Resonant laser ionization and mass separation of

Jake D Johnson, Michael Heines, Frank Bruchertseifer, Eric Chevallay, Thomas E Cocolios, Kristof Dockx, Charlotte Duchemin, Stephan Heinitz, Reinhard Heinke, Sophie Hurier and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Quantification of traceScientific reports · 2025
    Article
  3. Production and purification of molecularJournal of radioanalytical and nuclear chemistry · 2025
    Article
  4. Article
  5. Review
  6. Targeted Alpha Therapy: All We Need to Know aboutPharmaceuticals (Basel, Switzerland) · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jake D JohnsonKU Leuven, IKS, 3000, Leuven, Belgium. jake.johnson@kuleuven.be.
Michael HeinesKU Leuven, IKS, 3000, Leuven, Belgium.
Frank BruchertseiferJRC, Karlsruhe, Germany.
Eric ChevallayCERN, 1211, Geneva, Switzerland.
Thomas E CocoliosKU Leuven, IKS, 3000, Leuven, Belgium.
Kristof DockxKU Leuven, IKS, 3000, Leuven, Belgium.
Charlotte DucheminKU Leuven, IKS, 3000, Leuven, Belgium.
Stephan HeinitzBelgian Nuclear Research Centre SCK CEN, Mol, Belgium.
Reinhard HeinkeKU Leuven, IKS, 3000, Leuven, Belgium.
Sophie HurierKU Leuven, IKS, 3000, Leuven, Belgium.
Laura LambertCERN, 1211, Geneva, Switzerland.
Benji LeendersBelgian Nuclear Research Centre SCK CEN, Mol, Belgium.
Hanna SkliarovaBelgian Nuclear Research Centre SCK CEN, Mol, Belgium.
Thierry StoraCERN, 1211, Geneva, Switzerland.
Wiktoria WojtaczkaKU Leuven, IKS, 3000, Leuven, Belgium.

Funding

Horizon 2020 Framework Programme 101008571HORIZON EUROPE Marie Sklodowska-Curie Actions 861198
6 · The paper itself

Abstract

[Formula: see text]Ac is a radio-isotope that can be linked to biological vector molecules to treat certain distributed cancers using targeted alpha therapy. However, developing [Formula: see text]Ac-labelled radiopharmaceuticals remains a challenge due to the supply shortage of pure [Formula: see text]Ac itself. Several techniques to obtain pure [Formula: see text]Ac are being investigated, amongst which is the high-energy proton spallation of thorium or uranium combined with resonant laser ionization and mass separation. As a proof-of-principle, we perform off-line resonant ionization mass spectrometry on two samples of [Formula: see text]Ac, each with a known activity, in different chemical environments. We report overall operational collection efficiencies of 10.1(2)% and 9.9(8)% for the cases in which the [Formula: see text]Ac was deposited on a rhenium surface and a ThO[Formula: see text] mimic target matrix respectively. The bottleneck of the technique was the laser ionization efficiency, which was deduced to be 15.1(6)%.

Identifiers

PMID36693865
PMCPMC9873802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.